Metformin Inhibits Cardiac Fibroblast Differentiation By Promoting Fatty Acid Β-Oxidation: Implications For Age-Associated Cardiac Fibrosis
As we age, our hearts can develop a condition called cardiac fibrosis, where scar tissue builds up, making the heart stiff and less efficient, ultimately leading to heart failure. This scarring is largely due to the activation of specialized cells called fibroblasts, which start producing excessive amounts of structural proteins, essentially creating scar tissue. Aging exacerbates this process, often linked to metabolic stress and impaired function of mitochondria, the powerhouses of our cells.
Recent research has shed light on a potential therapeutic approach using metformin, a widely used medication. The study revealed that metformin significantly reduces the activation of these cardiac fibroblasts and also mitigates a related aging-like cellular process. This beneficial effect is achieved by enhancing a metabolic pathway known as fatty acid β-oxidation (FAO), which is the process by which cells break down fats to generate energy. The improved FAO, in turn, leads to better mitochondrial function.
Crucially, when the researchers blocked FAO, the positive effects of the drug on fibroblast activation and cellular aging were largely reversed, underscoring the vital role of fat metabolism in this process. Mechanistically, the drug was found to increase the activity of a key enzyme, CPT1, which is essential for burning fats. These findings suggest that by promoting efficient fat burning and preserving mitochondrial health, this medication could offer a promising strategy to combat age-associated heart scarring and improve overall heart health.
Source: link to paper